Two research teams have identified key proteins that help Parkinson's disease spread through the brain. Yale scientists pinpointed mGluR4 and NPDC1 as transporters of the toxic protein α-synuclein, while UPenn researchers found that blocking GPNMB — released by immune cells — halted the spread in lab experiments. Both discoveries point toward therapies that could slow or stop disease progression, not just manage symptoms.
Two new studies are shedding light on one of Parkinson's disease's biggest mysteries: how the toxic protein α-synuclein hijacks healthy brain cells and spreads damage across the brain. Yale School of Medicine researchers identified two surface proteins — mGluR4 and NPDC1 — on dopamine-producing neurons that act as transporters, ferrying misfolded α-synuclein into healthy cells. When mice were engineered to lack these proteins, they were protected from disease progression and showed dramatically reduced symptoms.
Meanwhile, University of Pennsylvania researchers zeroed in on GPNMB, a protein released by the brain's immune cells (microglia) when neurons are damaged. This sets off a self-reinforcing cycle: α-synuclein damages neurons, triggering GPNMB release, which accelerates further spread. Antibodies blocking GPNMB successfully stopped this cycle in lab experiments, and analysis of 1,675 human brain samples confirmed the protein's role in disease progression.
Key Takeaways:
Why it matters: About 1.1 million Americans live with Parkinson's, and no approved treatment currently slows its progression. With an aging population driving rising case numbers, these findings offer a genuine roadmap toward therapies that could stop the disease in its tracks — not just ease its symptoms.
